Title:
A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma
Phase:
II
Contact:
Margit Peters-Hornig / Kontaktperson
Email-Address:
Margit.Peters-Hornig@med.uni-heidelberg.de
Clinical Investigator:
Prof. Dr. Carsten Grüllich
Registration:
Keine Registernummer angegeben.
EudraCT-Number:
(siehe EU klinisches Studienregister)
2016-000706-12